MoonLake Immunotherapeutics
MoonLake Immunotherapeutics
MLTX
NASDAQ
48.44
USD
-7.73%
About
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases.
The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 153.2K |
| Three Month Average Volume | 6.9M |
| High Low | |
| Fifty-Two Week High | 64.98 USD |
| Fifty-Two Week Low | 35.11 USD |
| Fifty-Two Week High Date | 12 Feb 2024 |
| Fifty-Two Week Low Date | 06 Nov 2023 |
| Price and Volume | |
| Current Price | 46.79 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 7.29% |
| Thirteen Week Relative Price Change | 7.52% |
| Twenty-Six Week Relative Price Change | -16.43% |
| Fifty-Two Week Relative Price Change | -35.14% |
| Year-to-Date Relative Price Change | -34.57% |
| Price Change | |
| One Day Price Change | -1.45% |
| Thirteen Week Price Change | 15.08% |
| Twenty-Six Week Price Change | -8.11% |
| Five Day Price Change | -5.99% |
| Fifty-Two Week Price Change | -18.73% |
| Year-to-Date Price Change | -22.52% |
| Month-to-Date Price Change | 12.34% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 8.19753 USD |
| Book Value Per Share (Most Recent Quarter) | 8.28098 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 8.19753 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 8.28098 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.3109 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.73301 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.90427 USD |
| Normalized (Last Fiscal Year) | -0.73301 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.73301 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.90427 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.73301 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.90427 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 8.4511 USD |
| Cash Per Share (Most Recent Quarter) | 8.26724 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.89706 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.97353 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.08165 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -66.51% |
| EPS Change (Trailing Twelve Months) | 0.63% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 6 |
| Price to Tangible Book (Most Recent Quarter) | 6 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -519,799,600 |
| Net Debt (Last Fiscal Year) | -511,008,200 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 6 |
| Price to Book (Most Recent Quarter) | 6 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 52 |
| Current Ratio (Most Recent Quarter) | 44 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -43,062,800 |
| Free Cash Flow (Trailing Twelve Months) | -64,645,460 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -14.61% |
| Return on Assets (Trailing Twelve Months) | -11.08% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -13.22% |
| Return on Equity (Trailing Twelve Months) | -10.85% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -16.09% |
| Return on Investment (Trailing Twelve Months) | -11.49% |
| Return on Investment (5 Year) | -99,999.99% |